Drug Trial Radar · NCT02607865
Efficacy and Long-term Safety of Oral Semaglutide Versus Sitagliptin in Subjects With Type 2 Diabetes
Last checked: Nov 19, 2026Latest source record: Jul 20, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,864
Actual
Start
Feb 15, 2016
Primary completion
Feb 14, 2017
Study completion Mar 28, 2018
Sponsor
- Lead sponsor
- Novo Nordisk A/SNovo Nordisk (NVO)
- Sponsor type
- Industry
- First posted
- Nov 18, 2015
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This trial is conducted globally. The aim of the trial is to investigate efficacy and long-term safety of oral semaglutide versus sitagliptin in subjects with type 2 diabetes.
Conditions
- Diabetes
- Diabetes Mellitus, Type 2
Interventions
semaglutideDrug
Oral administration once-daily
sitagliptinDrug
Oral administration once-daily
placeboDrug
Oral administration once-daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in HbA1c: Week 26Time frame: Week 0, week 26
Locations
242 sites in 15 countries. Site status is shown where the registry gives one.
Novo Nordisk Investigational Site
Anniston, Alabama
Novo Nordisk Investigational Site
Birmingham, Alabama
Novo Nordisk Investigational Site
Tuscumbia, Alabama
Novo Nordisk Investigational Site
Glendale, Arizona
Novo Nordisk Investigational Site
Little Rock, Arkansas
Novo Nordisk Investigational Site
Carmichael, California
Novo Nordisk Investigational Site
Coronado, California
Novo Nordisk Investigational Site
Encino, California
Novo Nordisk Investigational Site
Fresno, California
Novo Nordisk Investigational Site
Los Alamitos, California
Novo Nordisk Investigational Site
Palm Springs, California
Novo Nordisk Investigational Site
Poway, California
Novo Nordisk Investigational Site
Walnut Creek, California
Novo Nordisk Investigational Site
Denver, Colorado
Novo Nordisk Investigational Site
Kissimmee, Florida
Novo Nordisk Investigational Site
New Port Richey, Florida
Novo Nordisk Investigational Site
Palm Harbor, Florida
Novo Nordisk Investigational Site
Plantation, Florida
Novo Nordisk Investigational Site
Port Charlotte, Florida
Novo Nordisk Investigational Site
Spring Hill, Florida
Novo Nordisk Investigational Site
Tampa, Florida
Novo Nordisk Investigational Site
Marietta, Georgia
Novo Nordisk Investigational Site
Perry, Georgia
Novo Nordisk Investigational Site
Honolulu, Hawaii
Novo Nordisk Investigational Site
Meridian, Idaho
Novo Nordisk Investigational Site
Gurnee, Illinois
Novo Nordisk Investigational Site
Peoria, Illinois
Novo Nordisk Investigational Site
Peoria, Illinois
Novo Nordisk Investigational Site
Avon, Indiana
Novo Nordisk Investigational Site
Park City, Kansas
Novo Nordisk Investigational Site
Lexington, Kentucky
Novo Nordisk Investigational Site
Louisville, Kentucky
Novo Nordisk Investigational Site
Paducah, Kentucky
Novo Nordisk Investigational Site
Paducah, Kentucky
Novo Nordisk Investigational Site
Metairie, Louisiana
Novo Nordisk Investigational Site
Natchitoches, Louisiana
Novo Nordisk Investigational Site
Shreveport, Louisiana
Novo Nordisk Investigational Site
Rockville, Maryland
Novo Nordisk Investigational Site
Waltham, Massachusetts
Novo Nordisk Investigational Site
Flint, Michigan
Showing 40 of 242 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.